<DOC>
	<DOC>NCT01250730</DOC>
	<brief_summary>The purpose of this study is to investigate the pharmacokinetics of single doses of PF-02341066 (150, 250, and 400 mg) in the fasted condition in Japanese healthy male volunteers.</brief_summary>
	<brief_title>A Study In Japanese Healthy Male Volunteers To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-02341066</brief_title>
	<detailed_description>The purpose of this study is to investigate the pharmacokinetics of single doses of PF-02341066 (150, 250, and 400 mg) in the fasted condition in Japanese healthy male volunteers.</detailed_description>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Healthy male subjects, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12lead ECG and clinical laboratory tests). Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg Subjects who are smoking, Subjects with evidence of disease, Subjects with conditions affecting absorption, Subjects with treatment with other investigational drug within 30 days, Subjects with history of regular alcohol consumption, Subjects with use of prescription, nonprescription drugs and dietary supplement within 28 days, Subjects with blood donation of approximately 400 mL within 3 months or 200 mL within 1 month prior to dosing</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>PK profile in Japanese healthy male volunteers</keyword>
</DOC>